Section 1 of 6
Terms and abbreviations
1 evidence topic · 0 sources
| Abbreviation | Term |
|---|---|
| A-aDO2 | Alveolar-arterial oxygen difference |
| AHFS | American Hospital Formulary Service |
| aPAP | Autoimmune pulmonary alveolar proteinosis |
| ATC | Anatomical Therapeutic Chemical classification |
| ATS | American Thoracic Society |
| BLA | Biologics License Application |
| CI | Confidence interval |
| COVID-19 | Coronavirus disease 2019 |
| CYFRA21-1 | Cytokeratin 19 fragment |
| DBSC | Dried blood spot card |
| DLCO | Diffusing capacity of the lungs for carbon monoxide |
| DLCOadj | Diffusing capacity of the lungs for carbon monoxide adjusted for hemoglobin |
| EC | Exercise capacity |
| EMA | European Medicines Agency |
| EQ-5D-5L | EuroQol 5 Dimensions, 5 Levels |
| ERS | European Respiratory Society |
| ETD | Estimated treatment difference |
| FAS | Full analysis set |
| FDA | U.S. Food and Drug Administration |
| GM-CSF | Granulocyte-macrophage colony-stimulating factor |
| GMAb | GM-CSF autoantibody |
| HRQoL | Health-related quality of life |
| IMP | Investigational medicinal product |
| KL-6 | Krebs von den Lungen-6 |
| LDH | Lactate dehydrogenase |
| LSM | Least-squares mean |
| MAA | Marketing Authorisation Application |
| MAD | Multiple ascending dose |
| MD | Mean difference |
| MET | Metabolic equivalent |
| MHRA | Medicines and Healthcare products Regulatory Agency |
| MOL-MOL | Molgramostim during both double-blind and open-label treatment |
| NS | Not significant |
| PAP | Pulmonary alveolar proteinosis |
| PBO | Placebo |
| PD | Pharmacodynamics |
| PDUFA | Prescription Drug User Fee Act |
| PK | Pharmacokinetics |
| PRO | Patient-reported outcome |
| RTF | Refusal to File |
| SAD | Single ascending dose |
| SGRQ | St. George’s Respiratory Questionnaire |
| SGRQ-A | St. George’s Respiratory Questionnaire Activity score |
| WBC | White blood cell |
| WLL | Whole lung lavage |